Form 8-K Jazz Pharmaceuticals For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
November 6, 2019 11:26 AM ESTOppenheimer analyst Esther Rajavelu raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $179.00 (from $176.00) while maintaining a Outperform rating.
The analyst commented, "We update our JAZZ model following 3Q19 results that topped our estimates for both revenue (Xyrem beat) and adjusted earnings.... More
